Clinical Trial

A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, multi-center phase II/III study to evaluate the efficacy and safety of Recombinant Botulinum Toxin Type A (YY001) for injection in the treatment of upper limb spasticity in adults
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-14.
Trial Details
NCT Number NCT06783114
Lead Sponsor Chongqing Claruvis Pharmaceutical Co., Ltd.
Conditions Upper Limb Spasticity
Enrollment 254 participants
Start Date 2024-09-14
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-22